Creating a hospital register for patients with heart failure and preserved ejection fraction
Official title: Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
Run by National Medical Research Center for Therapy and Preventive Medicine · NCT06114498 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study is trying to create a hospital registry for patients with heart failure and preserved ejection fraction to better understand their health and improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 40 Years to 80 Years |
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | National Medical Research Center for Therapy and Preventive Medicine Government |
| Drugs / interventions | Chemotherapy |
| Locations | 2 sites (Moscow and 1 other locations) |
| Trial ID | NCT06114498 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients hospitalized with acute decompensated heart failure showing symptoms such as shortness of breath and pulmonary edema.
✕Probably not a fit
Patients who refuse to provide informed consent or do not meet the clinical criteria for acute decompensated heart failure will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to establish a comprehensive hospital register for patients experiencing acute decompensated heart failure with preserved ejection fraction (HFpEF). It will assess various factors including gender characteristics, clinical history, body composition, and markers of inflammation to understand their impact on patient outcomes. The study will involve collecting data from hospitalized patients, analyzing their comorbid conditions, and evaluating treatment approaches both before and during hospitalization. The goal is to identify predictors of adverse outcomes and optimize treatment strategies for this patient population.
Why it matters
Potential benefit: If successful, this study could lead to improved management and outcomes for patients with heart failure and preserved ejection fraction.
How similar studies have gone: While the approach of creating a comprehensive register for HFpEF patients is not widely tested, similar studies focusing on heart failure management have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: All patients hospitalized with a clinical picture of acute decompensation of heart failure (shortness of breath, orthopnea, clinical signs of "cardiac asthma" and/or "pulmonary edema") in the city clinical hospital named after. V.V. Veresaeva, Moscow. Patients with a confirmed diagnosis in accordance with instrumental (EchoCG) and/or laboratory criteria. Exclusion Criteria: Refusal to sign informed consent to participate in a clinical trial and to process personal data.
Where it's running
-
Moscow State Clinical Hospital named after V.V. Veresaev
Moscow, Russian Federation Recruiting -
National Medical Research Center for Therapy and Preventive Medicine
Moscow, Russian Federation Recruiting
Study contacts
- Principal investigator: Yury Timfeev, PhD — National Medical Research Center for Therapy and Preventive Medicine
- Study coordinator: Yury Timofeev, phD
- Email: Timofeev_lab@mail.ru
- Phone: 89150104788
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Remote rehabilitation for HFpEF patients using telerehabilitation
A home-based telerehabilitation program is being tested to see if it is safe and helpful for people with heart failure with preserved ejection fraction.
-
EDG-15400 in adults with HFpEF: a phase 2 study
This phase 2 study tests different doses of EDG-15400 against placebo in adults with HFpEF to see if it is safe and tolerable.
-
Incretin therapy with tirzepatide for obesity-related HFpEF
A 15-month study will test whether tirzepatide helps people with obesity and HFpEF by reducing plasma volume.
-
Characterizing phenotypes of acute heart failure
This project will try to see if heart function measures, imaging features (radiomics), and blood biomarkers can predict outcomes for adults hospitalized with acute heart failure, including cardiogenic shock.
-
Cardiac rehabilitation using inspiratory muscle training plus leg electrical stimulation for decompensated heart failure
This trial will test whether adding inspiratory muscle training and lower‑limb electrical stimulation to usual care helps hospitalized patients aged 45–65 with decompensated heart failure and ejection fraction under 40% breathe better and improve functional ability.
-
Adding vericiguat to guideline heart-failure therapy for people with decompensated heart failure
This trial will test whether giving vericiguat, on top of usual guideline-based drugs, helps people with decompensated heart failure seen in the emergency department.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.